Clinical Trial Detail

NCT ID NCT03822117
Title Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Incyte Corporation
Indications

Advanced Solid Tumor

Therapies

Pemigatinib

Age Groups: adult senior

Additional content available in CKB BOOST